Publications

Publications from OUS - Anti-cancer therapy with immunotoxin

26 publications found

Publications 2021

  1. Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
    Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
    Cancers (Basel), 13 (11)
    DOI 10.3390/cancers13112819, PubMed 34198773
  2. Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
    Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Ann Surg Oncol, 28 (9), 5252-5262
    DOI 10.1245/s10434-021-10022-0, PubMed 34019185

Publications 2020

  1. Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y (2020)
    Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma
    Ann Diagn Pathol, 46, 151483
    DOI 10.1016/j.anndiagpath.2020.151483, PubMed 32143173

Publications 2019

  1. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
    Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
    Acta Oncol, 59 (4), 404-409
    DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
  2. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
    ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
    Eur J Surg Oncol, 47 (1), 134-138
    DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
  3. Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
    Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
    Front Oncol, 9, 1302
    DOI 10.3389/fonc.2019.01302, PubMed 31921617

Publications 2017

  1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
    MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
    Oncotarget, 8 (37), 61800-61809
    DOI 10.18632/oncotarget.18694, PubMed 28977905
  2. Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
    Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
    Pigment Cell Melanoma Res, 30 (5), 467-476
    DOI 10.1111/pcmr.12599, PubMed 28513992
  3. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
    Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
    Ann Surg Oncol, 24 (7), 1916-1922
    DOI 10.1245/s10434-017-5814-6, PubMed 28224367
  4. Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M (2017)
    Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma
    Exp Mol Pathol, 103 (2), 218-228
    DOI 10.1016/j.yexmp.2017.10.001, PubMed 29050853
  5. Zanjani LS, Madjd Z, Abolhasani M, Rasti A, Fodstad O, Andersson Y, Asgari M (2017)
    Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma
    Biomark Med, 12 (1), 45-61
    DOI 10.2217/bmm-2017-0142, PubMed 29243496

Publications 2015

  1. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
    Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
    Br J Cancer, 113 (11), 1548-55
    DOI 10.1038/bjc.2015.380, PubMed 26554649
  2. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
    Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
    BMC Cancer, 15, 543
    DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Publications 2014

  1. Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
    The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
    J Ovarian Res, 7, 23
    DOI 10.1186/1757-2215-7-23, PubMed 24528603

Publications 2013

  1. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
    Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
    Int J Cancer, 133 (6), 1497-506
    DOI 10.1002/ijc.28158, PubMed 23494569

Publications 2011

  1. Risberg K, Fodstad Ø, Andersson Y (2011)
    Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma
    PLoS One, 6 (9), e24012
    DOI 10.1371/journal.pone.0024012, PubMed 21915275
  2. Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
    Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
    J Immunother, 34 (5), 438-47
    DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Publications 2010

  1. Risberg K, Fodstad O, Andersson Y (2010)
    Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells
    J Immunother, 33 (3), 272-8
    DOI 10.1097/CJI.0b013e3181c54991, PubMed 20445347
  2. Risberg K, Fodstad O, Andersson Y (2010)
    Immunotoxins: a promising treatment modality for metastatic melanoma?
    Ochsner J, 10 (3), 193-9
    PubMed 21603377
  3. Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y (2010)
    A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
    Cancer Immunol Immunother, 59 (11), 1665-74
    DOI 10.1007/s00262-010-0892-3, PubMed 20635083

Publications 2009

  1. Risberg K, Fodstad Ø, Andersson Y (2009)
    The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro
    Int J Cancer, 125 (1), 23-33
    DOI 10.1002/ijc.24317, PubMed 19350633

Publications 2006

  1. Andersson Y, Le H, Juell S, Fodstad Ø (2006)
    AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death
    Mol Cancer Ther, 5 (4), 1050-9
    DOI 10.1158/1535-7163.MCT-05-0318, PubMed 16648577
  2. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
    DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
    Anticancer Res, 26 (3A), 1909-16
    PubMed 16827124

Publications 2005

  1. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
    Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
    Mol Cancer Ther, 4 (8), 1231-8
    DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439

Publications 2004

  1. Andersson Y, Juell S, Fodstad Ø (2004)
    Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin
    Int J Cancer, 112 (3), 475-83
    DOI 10.1002/ijc.20371, PubMed 15382075
  2. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
    Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
    Radiother Oncol, 72 (3), 305-10
    DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729
 
Scroll to top